India, April 17 -- As far as the pharmaceutical sector is concerned, the strategy used by a company for allocating capital often shows how confident they are. In this regard, today we get to see an important statement from Windlas Biotech Limited in which it decides to buy back its own stocks through tender offers.

This has been decided after considering the successful financial performance of the company. The objective of this buyback is to maximize returns for the shareholders, and as the price is being quoted at a premium to the prevailing rate, the stock has become highly volatile.

Currently, the stock is trading at Rs.870.00 with market capitalization of Rs.1,833 crore and is displaying extreme volatility due to the news update. Th...